Novartis Sees Space For Sandoz But In A Slimmer Streamlined Form
Executive Summary
Sandoz has a place within Novartis as a more autonomous unit, the Swiss group’s CEO Vas Narasimhan says. But the generics and biosimilars division will have to sharpen up, aided by a 7% workforce cut.
You may also be interested in...
Generics Bulletin Explains: Sandoz’s Spinoff From Novartis
Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.
Saynor Seeks To Take Sandoz Back To Basics
In an exclusive interview with Generics Bulletin, Sandoz’ CEO Richard Saynor explains how he wants the Novartis division to focus on the industry basics of being first-to-market with cost-competitive generics and biosimilars.
Novartis Selects GSK’s Saynor As Next Sandoz CEO
GlaxoSmithKline’s established products head, Richard Saynor, will return to Sandoz later this year to lead the Novartis division.